Skip to content

The effects and mechanism of treatment with liraglutide on depression in patients with obesity

The effects and mechanism of treatment with liraglutide on depression in patients with obesity

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065628
Enrollment
Unknown
Registered
2022-11-10
Start date
2022-11-11
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

subjects with liraglutide:liraglutide

Sponsors

North District, The Municipal Hospital of Suzhou, Suzhou, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 39 Years

Inclusion criteria

Inclusion criteria: 1. Age from 14-39 years old; 2. BMI >= 28 kg/m^2; 3. Deny a history of depression or other related mental illness and deny the history of taking antidepressant medication.

Exclusion criteria

Exclusion criteria: 1. Patients with pancreatitis or pancreatic cancer; 2. Patients with severe heart/kidney/liver failure; 3. Women in pregnancy or lactation; 4. Patients with severe infections and neoplastic diseases; 5. Patients with pathological obesity (Cushing's syndrome, hypothyroidism, pituitary diseases); 6. Patients with the treatments of other bariatric drugs or metabolic surgery; 7. Patients with diabetes with HbA1C >8%.

Design outcomes

Primary

MeasureTime frame
Weight;Depression score;Quality of Life;5-hydroxytryptamine;5-hydroxyindoleacetic acid;

Countries

China

Contacts

Public ContactHonghong Lu

North District, The Municipal Hospital of Suzhou, Suzhou, China

szsynfm@163.com+86 512 62363016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026